In diffuse midline glioma, H3 K27-altered, MET alterations including amplification and activating point mutations have been reported to occur sporadically (8.6–15.0%) (Hoffman et al., 2016; Porkholm et al., 2018; Dufour et al., 2020). This evidence concerns the gene MET and diffuse midline glioma.